- End-to-end diligence for public (long/short) and private (newco through crossover) investment opportunities across medtech, tools, services, AI drug design, diagnostics, and oncology including sourcing, financial modeling, valuation, and comprehensive investment thesis. - Re-underwriting of public investments in CTKB and RXST via close collaboration with management teams.- Origination team member for two healthcare services newcos in stealth mode.

- Diligence and portfolio support included analysis of data readouts from academic conferences and press releases, landscaping reports, market sizing, data review, expert consultations, and pitching investment theses.- Supported the launch of RA’s Health Technologies and Services team. - Diligence toward investments in CTKB, RXST, TIL, KNTE, Exo, Nodexus, Synthekine, Asher, and New Equilibrium Biosciences.

Nodexus is a private research tools company launching a microfluidic cell sorter (the NX One) differentiated by lower cost and higher performance relative to existing instruments in its class.

Exo Imaging is a private AI-enabled medtech company launching a best-in-class handheld point-of-care ultrasound imaging device (Iris) based on novel pMUT semiconductor tech and companion enterprise software (ExoWorks).

Conceived of first-in-class platform technologies which together formed the basis for company-creation proposals. Due diligence included extensive scientific literature research, interviewing dozens of leading experts, and designing proof-of-concept wet lab experiments. Presented newco proposals to CEO and partnership.

Supported deal screening and diligence. Surveyed the landscape of a medtech sector of interest to the firm, documented findings in a report, and presented findings to the partnership. Attended VC University training program co-hosted by the University of California, Berkeley and the National Venture Capital Association.

Contributed to the development of microfluidics-based point-of-care qPCR diagnostic devices for the Bill and Melinda Gates Foundation and Micronics, passive vaccine storage for Intellectual Ventures Laboratory, and autologous cell therapy production equipment for Sotio.

Led hardware R&D efforts toward the production of an assay for the isolation and imaging of rare circulating tumor cells (CTCs – as few as 1 in 50 billion) from whole human blood. Outfitted and oversaw a small machine shop and laser metrology lab. Efforts resulted in 17 patent applications.

Designed and executed a drug delivery study in which cancer cells were exposed in vitro to high intensity focused ultrasound (HIFU) in the presence of custom-designed nanoemulsions in order to transiently increase cell membrane permeability and thus promote the passage of therapeutic agents (siRNA and others) into cells. Designed and fabricated an automated exposure system to facilitate the sequential exposure of numerous samples and to monitor for acoustic signals indicative of stable and inertial cavitation. The study established proof of concept and explored the relationship between the type of cavitation produced and the degree of cell membrane permeabilization realized.

Developed and characterized a lipid-shelled, gas-filled ultrasound contrast agent (UCA) for internal use at CIMU. The primary objective was to circumvent cost and availability issues hindering the purchase of commercially produced UCAs. Contributions to sourcing, processing, preparation, and storage resulted in a comparable solution that could be produced in-house at a 99% cost savings.